Prostate-specific antigen density: The role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma
✍ Scribed by L. I§ikay; Ö. Yaman; M. Bozlu; Y. Z. Müftüoĝlu; O. Göĝü§
- Book ID
- 110553894
- Publisher
- Springer Netherlands
- Year
- 1995
- Tongue
- English
- Weight
- 258 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0301-1623
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Prostate‐specific antigen (PSA), as measured in peripheral blood, is currently the most widely used marker for the assessment of tumor burden in the longitudinal study of patients with carcinoma of the prostate (PCA). Studies from other laboratories have led to the conclusion that a giv
Background. Prostate specific antigen (PSA) does not appear to have the specificity to distinguish between benign prostate hyperplasia and cancer when the PSA is low. PSA density is thought by many to improve the specificity for cancer; however, this theory remains controversial. Methods. The autho
Background. Prostate specific antigen (PSA) is useful as a tumor marker for monitoring patients with prostate cancer after definitive therapy. Limitations have been noted when PSA was used for the early detection of prostate cancer. The use of prostate specific antigen density [PSAD = PSA (ng/ml)/pr